Peer-Reviewed Publication
J Fungi (Basel)2026;12(8)July 24, 2026Journal Article
In Vitro Activity and In Vivo Efficacy in a Murine Model of Rezafungin, Anidulafungin, Caspofungin, and Micafungin Against the Fifth Clade of Candida (Candidozyma) auris.
Dávid Balázsi1,2, Jacques F Meis3,4, Jeffrey B Locke5, Gergely Udvarhelyi1,2, Zoltán Tóth1,6, Lajos Forgács1, Csaba Kósa7, Renátó Kovács1,6, László Majoros1,6
1Department of Medical Microbiology, Faculty of Medicine, University of Debrecen, Nagyerdei krt. 98, 4032 Debrecen, Hungary.
2Doctoral School of Pharmaceutical Sciences, University of Debrecen, Nagyerdei krt. 98, 4032 Debrecen, Hungary.
3Centre of Expertise in Mycology, Radboudumc and Canisius Wilhelmina Hospital, 6525 GA Nijmegen, The Netherlands.
4Institute of Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Excellence Center for Medical Mycology (ECMM), University of Cologne, 50923 Cologne, Germany.
5Elion Therapeutics, Inc., 1 Lincoln Street, Suite 30-120, Boston, MA 02111, USA.
6Medical Microbiology, Clinical Centre, University of Debrecen, 4032 Debrecen, Hungary.
7Department of Surgery, Clinical Centre, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary.
Abstract
Objectives: The aim of our study was to investigate the in vitro activity and in vivo efficacy of rezafungin, anidulafungin, caspofungin and micafungin against Candida auris isolates belonging to clade V. Methods: Five clinical isolates were evaluated (IFRC2087, IFRC4050, MRL40, TMML616 and TMML617). Echinocandin MICs, according to CLSI M27-Ed4, and killing activities were determined in RPMI-1640.…
Create a free account to keep reading
Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.
Want unlimited research access? See Pro plans